Advanced search
Publication Cover
Current Medical Research and Opinion Volume 20, 2004 - Issue 12
Submit an article Journal homepage
182
Views
16
CrossRef citations to date
0
Altmetric
Research Article

Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model

Mark B. Abelson Ophthalmic Research Associates, North Andover, MA, USA; Schepens Eye Research Institute, Boston, MA, USA; Department of Ophthalmology, Harvard Medical School, Boston, MA, USA
&
Jack V. Greiner Schepens Eye Research Institute, Boston, MA, USA; Department of Ophthalmology, Harvard Medical School, Boston, MA, USA
Pages 1953-1958 | Accepted 08 Aug 2004, Published online: 16 Nov 2004

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Alexei Gonzalez-Estrada, Keerthi Reddy, Ves Dimov & Frank Eidelman. (2017) Olopatadine hydrochloride ophthalmic solution for the treatment of allergic conjunctivitis. Expert Opinion on Pharmacotherapy 18:11, pages 1137-1143.
Read now
Craig F McCabe & Shannon E McCabe. (2012) Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference. Clinical Ophthalmology 6, pages 1731-1738.
Read now
Andrea Leonardi & Luigi Quintieri. (2010) Olopatadine: a drug for allergic conjunctivitis targeting the mast cell. Expert Opinion on Pharmacotherapy 11:6, pages 969-981.
Read now
Eiichi Uchio. (2008) Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops. Clinical Ophthalmology 2:3, pages 525-531.
Read now
Steven J Lichtenstein & Mark B Abelson. (2006) Pharmacology, clinical efficacy and safety of olopatadine hydrochloride. Expert Review of Clinical Immunology 2:3, pages 341-351.
Read now

Articles from other publishers (11)

J.-L. Fauquert, M. Jedrzejczak-Czechowicz, C. Rondon, V. Calder, D. Silva, B. K. Kvenshagen, I. Callebaut, P. Allegri, N. Santos, S. Doan, D. Perez Formigo, F. Chiambaretta, L. Delgado & A. Leonardi. (2017) Conjunctival allergen provocation test : guidelines for daily practice. Allergy 72:1, pages 43-54.
Crossref
Pranav Gupta, Etti Goyal & Jaya Devendra. (2016) Comparative Study of 0.1% Olopatadine vs 0.05% Cyclosporine in Patients of Recalcitrant Vernal Keratoconjunctivitis. International Journal of Advanced and Integrated Medical Sciences 1:4, pages 139-142.
Crossref
Rajani Mathur & Renu Agarwal. 2016. Pharmacology of Ocular Therapeutics. Pharmacology of Ocular Therapeutics 229 244 .
Atsuki Fukushima & Nobuyuki Ebihara. (2014) Efficacy of Olopatadine versus Epinastine for Treating Allergic Conjunctivitis Caused by Japanese Cedar Pollen: A Double-Blind Randomized Controlled Trial. Advances in Therapy 31:10, pages 1045-1058.
Crossref
Virginia Miraldi Utz & Aaron R. Kaufman. (2014) Allergic Eye Disease. Pediatric Clinics of North America 61:3, pages 607-620.
Crossref
Paramdeep S. Bilkhu, James S. Wolffsohn & Shehzad A. Naroo. (2012) A review of non-pharmacological and pharmacological management of seasonal and perennial allergic conjunctivitis. Contact Lens and Anterior Eye 35:1, pages 9-16.
Crossref
RP Rietveld, JP Cleveringa, GH Blom, MEJM Baggen, D Bink, JMT Oltheten & GM Van der Weele. 2011. NHG- Standaarden voor de huisarts 2011. NHG- Standaarden voor de huisarts 2011 215 235 .
Alessandro Lambiase, Alessandra Micera & Stefano Bonini. (2009) Multiple action agents and the eye: do they really stabilize mast cells?. Current Opinion in Allergy & Clinical Immunology 9:5, pages 454-465.
Crossref
R P Rietveld, J P Cleveringa, G H Blom, M E J M Baggen, D Bink, J M T Oltheten & G M Van der Weele. 2009. NHG-Standaarden voor de huisarts 2009. NHG-Standaarden voor de huisarts 2009 1077 1097 .
KARINA QUINONES & C. STEPHEN FOSTER. 2008. Managing the Allergic Patient. Managing the Allergic Patient 145 174 .
Beth Lillian Schultz. (2006) Pharmacology of ocular allergy. Current Opinion in Allergy & Clinical Immunology 6:5, pages 383-389.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.